Previous 10 | Next 10 |
BRISBANE, California and BASEL, Switzerland, June 04, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV ), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that Ly...
Stellar Biotechnologies (NASDAQ: SBOT ) +73% . More news on: Stellar Biotechnologies, Inc., Eltek Ltd., Williams-Sonoma, Inc., Stocks on the move, Read more ...
Myovant Sciences ( MYOV ) has priced its public offering of 15.51M common shares at $8.25 per share, for gross proceeds of $125M. More news on: Myovant Sciences Ltd., Read more ...
BRISBANE, Calif. and BASEL, Switzerland, May 30, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“ Myovant ”), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today anno...
Gainers: Obalon Therapeutics (NASDAQ: OBLN ) +42% . Eltek (NASDAQ: ELTK ) +35% . SilverSun Technologies (NASDAQ: SSNT ) +33% . MiMedx Group ( OTC:MDXG ) +31% . BioCryst Pharmaceuticals (NASDAQ: BCRX ) +19% . Tocagen (NASDAQ: TOCA ) +17% . Hydrogenics Corporation (NASDAQ: HYGS )...
Myovant Sciences (NYSE: MYOV ) is 8.8% lower after hours following a filing of a prospectus to offer $100M in shares . More news on: Myovant Sciences Ltd., Healthcare stocks news, Stocks on the move, Read more ...
BRISBANE, Calif. and BASEL, Switzerland, May 29, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“ Myovant ”), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today anno...
Myovant Sciences (NYSE: MYOV ): Q4 GAAP EPS of -$1.07 misses by $0.04 . More news on: Myovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical studies expected over next three quarters- BRISBANE, Calif. & BASEL, Switzerland, May 24, 2019 (GLOB...
Gainers: Big 5 Sporting Goods (NASDAQ: BGFV ) +26% . Novavax (NASDAQ: NVAX ) +25% . Asta Funding (NASDAQ: ASFI ) +20% . MeiraGTx Holdings (NASDAQ: MGTX ) +19% . Luokung Technology (NASDAQ: LKCO ) +18% . Key Energy Services (NYSE: KEG ) +17% . Verastem (NASDAQ: VSTM ) +17% . Su...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...